DESSAU, Germany & ROCKVILLE, Md.--(BUSINESS WIRE)--IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity (IDIQ) contract no. HHSN272201800011I to provide manufacturing of five E. coli Master Cell Banks.

The NIAID contract awarded in 2018 supports early research and development projects, including GMP manufacturing of Phase I/II clinical material for inclusion in Investigational New Drug (IND) applications and/or Biologic License Applications (BLA).

The purpose of this Task Order is to support a pentavalent vaccine by manufacturing 5 Master Cell Banks. All manufacturing activities will be conducted in the IDT Biologika Rockville, Maryland, facility.

“It is a great honor to be awarded with this Task Order and we are looking forward to meet the required milestones,” said IDT Biologika Chief Executive Officer Dr. Jürgen Betzing. “IDT has a long-standing history and proven track record of developing and manufacturing bacterial and virus-based vaccines. Our state-of-the-art manufacturing facility located in Rockville is well positioned to serve the current Task Order requirement.”

About IDT Biologika

IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards.

Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and Magdeburg. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland.